Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization						Print
																Related Pages
										**Question**: Should a Novavax COVID-19 vaccine booster dose (1 dose, 5μg antigen + 50μg Matrix-M adjuvant, IM, ≥2 months after completion of a COVID-19 vaccine primary series) be recommended for persons ages 18 years and older under an anticipated Emergency Use Authorization?
**Population**: People 18 years of age and older
**Intervention**: Novavax COVID-19 vaccine booster dose (1 dose, 5μg antigen + 50μg Matrix-M adjuvant, IM) ​**Background:**
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), in late 2019 has led to a global pandemic with dramatic societal and economic impact on individual persons and communities. In the United States, more than 96 million cases and more than 1 million COVID-19-associated deaths have been reported as of September 27, 2022.1 Persons of all ages are at risk for infection and severe disease. However, the risk for severe illness from COVID-19 is higher in people aged ≥65 years, those living in long-term care facilities, and those with chronic medical conditions. Additionally, there is a disproportionate burden of COVID-19 infections and deaths among racial and ethnic minority communities. Non-Hispanic Black, Hispanic/Latino (Hispanic) and American Indian/Alaska Native persons have experienced higher rates of disease, hospitalization and death compared with non-Hispanic White persons. This is likely related to inequities in social determinants of health that put racial and ethnic minority groups at increased risk for COVID-19, including overrepresentation among essential workers who have higher risk of exposure to COVID-19, lower incomes, reduced access to healthcare, or higher rates of comorbid conditions.
COVID-19 remains a significant threat, killing nearly 350 Americans per day.2 Being up to date with COVID-19 vaccines continues to provide strong protection against severe disease, hospitalization, and death in adults, including during Omicron variant predominance. However, protection is highest in adults who receive all recommended booster doses.3 About 48% of adults, which is approximately 96 million, are eligible for a booster and have not yet received a booster.4
On July 13, 2022, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Novavax monovalent COVID-19 vaccine for the prevention of COVID-19 in persons ages 18 years and older. Furthermore, on October 19, 2022, the FDA amended the Emergency Use Authorization (EUA) to allow for use of the Novavax monovalent COVID-19 vaccine as a first booster at least 6 months after completion of a primary series among persons ages 18 years who are unable or unwilling to receive a bivalent booster. Following FDA’s regulatory action, CDC signed a decision memo allowing Novavax monovalent COVID-19 boosters for persons ages 18 years and older on October 19, 2022. This action gives people ages 18 years and older the option to receive a Novavax monovalent booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed primary series vaccination but have not previously received a COVID-19 booster—and if they cannot or will not receive mRNA vaccines.
Additional background information supporting the interim ACIP recommendation on the use of Novavax COVID-19 vaccine can be found in the relevant publication of the recommendation referenced on the ACIP website.
__________________________
1https://covid.cdc.gov/covid-data-tracker/#trends_dailycases2 https://covid.cdc.gov/covid-data-tracker/#trends_dailydeaths_select_00 Accessed October 13, 2022.3 https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness Accessed October 13, 2022.4 https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-additional-dose-totalpop Data as of October 6, 2022, at 06:00am ET. Accessed October 13, 2022.
Updates to the EtR framework are presented below to address the evidence supporting the Novavax booster in persons ages 18 years and older. Please Note: There was not an ACIP vote for this EtR. Therefore, while the Work Group reviewed data to support the recommendation, they did not determine their judgement for any of the domains listed below:Benefits and Harms
Benefits and Harms
Criteria
Evidence
Additional InformationHow substantial are the desirable anticipated effects?
In an open-label continuation of the phase 3 randomized controlled trial among persons ages 18 years and older in the United States and Mexico, 12,777 participants received booster doses as of the data cut off (March 26, 2022). No clinical trial efficacy or real-world vaccine effectiveness data is yet available reflective of Novavax monovalent COVID-19 vaccine effectiveness against Omicron, or against Omicron BA.4/5. However, 298 participants provided immunogenicity data and the data suggest that receipt of a Novavax booster dose induces enhanced immune response to both ancestral strain (geometric mean fold rise [GMFR]: 3.4 [95% CI: 2.8, 4.0) and to Omicron BA.1 (geometric mean fold rise [GMFR]: 17.3 [95% CI: 10.6, 28.1) when compared with the Novavax primary series.1How substantial are the undesirable anticipated effects?
Data to date do not demonstrate concerning safety signals. Rare occurrences of myocarditis or pericarditis were identified in primary series clinical trials and in global post marketing data preceding primary series authorization in the United States. A single case of myocarditis was evident post-booster in clinical trials to date. Additional cases of myocarditis and pericarditis have occurred after Novavax COVID-19 vaccine in Australia, but cases after Novavax COVID-19 vaccine remain rare globally.
Furthermore, reactogenicity data following dose 2 and booster dose (dose 3) were available in 124 participants. Local and systemic reactogenicity appeared to be slightly more common after the booster dose than after dose 2, with severe (grade ≥3) systemic reactions reported in 23.2% and 15.1% of participants, respectively. Serious adverse events after the booster dose were reported by 43/12,777 participants (0.3%). No deaths occurred related to the booster dose.1Values **and Acceptability**
Values
Criteria
Evidence
Additional InformationDoes the target population feel that the desirable effects are large relative to undesirable effects?
In a survey designed by the CDC and University of Iowa/RAND Corporation to assess vaccination intentions for a protein-based COVID vaccine with or without adjuvant among unvaccinated Americans, 16% of unvaccinated respondents reported that they “probably” or “definitely” would get an adjuvanted protein-based COVID-19 vaccine. Additionally, vaccination intentions were significantly higher among men (21.9%) than among women (11.9%). However, vaccine intentions did not vary by US region, metropolitan status, age, or education.1
The survey collected data from January 27 – February 2, 2022, with a sample size of 541 respondents.1Is there important uncertainty about or variability in how much people value the main outcomes?
In relation to vaccination intentions for an adjuvanted protein subunit COVID vaccine among unvaccinated adults in the United States from January – February 2022, vaccination intentions were significantly lower among non-Hispanic White adults (9.6%) than among non-Hispanic Black adults (20.1%) or among Hispanic adults (19.5%).1Feasibility and Resource Use
Feasibility
Criteria
Evidence
Additional InformationIs the intervention feasible to implement?
Despite delivery of 841,300 doses, Novavax uptake has been limited in the United States. As of October 6, 2022, 32,992 doses have been administered since primary series authorization in July 2022.1Additionally, Novavax booster doses are of exactly the same formulation and dose as primary series doses, which means there is no “learning curve” for providers. Doses have been purchased by the United States Government and are already distributed across the United States. As remains the case with all COVID-19 vaccines, boosters will be administered without monetary cost to consumers.COVID-19 Vaccination Schedule for Adults who are NOT Moderately or Severely Immunocompromised
Recommendations for adults  who are not moderately or severely immunocompromised are shown below by primary series and includes 2-dose Moderna, Novavax, and Pfizer series in the first row and Janssen single-dose primary series in the second row. The recommendation has not changed; a bivalent booster continues to be recommended at least 2 months after the primary series or last monovalent booster dose. It can be either Pfizer or Moderna.
Chart showing Novavax adult scheduling
However, if adults who are not moderately or severely immunocompromised are unable or unwilling to get a bivalent mRNA booster, a monovalent Novavax booster dose is recommended at least 6 months after the primary series only without receipt of a previous booster(s).
Chart showing Novavax adult scheduling
COVID-19 Vaccination Schedule for Adults who ARE Moderately or Severely Immunocompromised
Recommendations for adults who are moderately or severely immunocompromised are shown below by primary series and includes 3-dose Moderna and Pfizer series in the first row, 2-dose Novavax in the second row, and Janssen single-dose primary series in the third row. Once again, the adult recommendation has not changed. Regardless of primary series received (the options shown in each of these rows), a bivalent booster is recommended 2 months after the primary series or last booster dose, and it can be Pfizer or Moderna.
Chart showing Novavax adult scheduling
Once more, if adults who are moderately or severely immunocompromised are unable or unwilling to get a bivalent mRNA booster, a monovalent Novavax booster dose is recommended at least 6 months after the primary series only without receipt of a previous booster(s).
Chart showing Novavax adult scheduling
Novavax Booster Recommendation
A monovalent Novavax booster dose (instead of a bivalent mRNA booster dose) may be used in limited situations in people ages 18 years and older who are:
Unable to receive an mRNA vaccine (i.e., contraindicated or in the absence of all supply)
Unwilling to receive an mRNA vaccine and would otherwise remain unvaccinated
Without history of prior COVID-19 booster receiptReferences
Benefits and Harms:
Novavax phase III randomized controlled trial, unpublished data from manufacturerValues and Acceptability:
CDC and University of Iowa/RAND survey, unpublishedFeasibility and Resource Use:
CDC COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-additional-dose-totalpop Accessed September 28, 2022Top of Page
							
					
							Last Reviewed:  November 7, 2022						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue